Roche's Wilserdly gains US clearance; adjuvant decision due 30 November
The US regulator has cleared giredestrant with everolimus for a biomarker-defined breast cancer group, and a second Wilserdly filing faces its review deadline in two weeks.
Roche has secured US marketing clearance for Wilserdly (giredestrant) in a narrow, biomarker-defined breast cancer population, and a second decision on the same drug is due within two weeks. The company announced the first approval on 16 November 2026. The information available gives no price, launch timing or sales expectations.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.